CHMP

July 2, 2019July 2, 2019

CHMP Recommends Expanding Imbruvica Use in the EU to Include 2 New Cancer Regimens

News

The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, has recommended the expansion of the current marketing authorization for Imbruvica (ibrutinib) to include ... Read more

November 15, 2017November 15, 2017

EMA Urges European Commission to Approve Takeda’s Adcetris as Therapy for CTCL

News

European regulators have endorsed the use of Takeda‘s Adcetris (brentuximab vedotin) to treat a specific type of cutaneous T-cell lymphoma (CTCL). The Brussels-based Committee for Medicinal Products for Human Use ... Read more

May 31, 2016May 31, 2016

CHMP Favors Approval of Adcetris (brentuximab vedotin) to Treat Post-Transplant Hodgkin Lymphoma

News

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the extension of the present provisional approval of Takeda Pharmaceutical’s Adcetris (brentuximab ... Read more

May 3, 2016May 3, 2016

CHMP Supports EU Approval of Obinutuzumab (Gazyvaro) to Treat Follicular Lymphoma

News

The EU Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Roche’s Gazyvaro (obinutuzumab), combined with bendamustine chemotherapy and then as monotherapy, to treat select patients with follicular lymphoma. The recommendation is as treatment for ... Read more